HIGHLIGHTS
- who: Dezhi Kang from the Department of Neurosurgery, Fujian Provincial Hospital South Branch, Fuzhou, China, Department of Neurosurgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China, Department of Neurosurgery, The First have published the paper: NPC2 as a Prognostic Biomarker for Glioblastoma Based on Integrated Bioinformatics Analysis and Cytological Experiments, in the Journal: (JOURNAL)
- what: The aim of this study is to explore the prognostic and carcinogenic potential of robust molecular signature that can improve the ability to predict GBM prognosis. The authors focus on investing the clinical prognostic significance of the NPC2 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.